Unnao gang-rape: Finally, FIR registered against BJP MLA, no decision on arrest

The International Cricket Council (ICC) today confirmed the ICC Men’s T20 World Cup in Australia 2020 has been postponed due to the ongoing COVID-19 pandemic

At today’s meeting of the IBC Board (the commercial subsidiary of the ICC), windows for the next three ICC men’s events were also agreed to bring clarity to the calendar and give the sport the best possible opportunity over the next three years to recover from the disruption caused by COVID-19.

The windows for the Men’s events are:

1. ICC Men’s T20 World Cup 2021 will be held October – November 2021 with the final on 14 November 2021

2. ICC Men’s T20 World Cup 2022 will be held October – November 2022 with the final on 13 November 2022

3. ICC Men’s Cricket World Cup 2023 will be held in India October – November 2023 with the final on 26 November 2023

The IBC Board agreed to continue to monitor the rapidly changing situation and assess all the information available in order to make a considered decision on future hosts to ensure the sport is able to stage safe and successful global events in 2021 and 2022.

The IBC Board will also continue to evaluate the situation in relation to being able to stage the ICC Women’s Cricket World Cup 2021 in New Zealand in February next year. In the meantime, planning for this event continues as scheduled.

The Board will also continue to evaluate the situation in relation to being able to stage the ICC Women’s Cricket World Cup 2021.

ICC Chief Executive Manu Sawhney said: “We have undertaken a comprehensive and complex contingency planning exercise and through this process, our number one priority has been to protect the health and safety of everyone involved in the sport.

“The decision to postpone the ICC Men’s T20 World Cup was taken after careful consideration of all of the options available to us and gives us the best possible opportunity of delivering two safe and successful T20 World Cups for fans around the world.

“Our Members now have the clarity they need around event windows to enable them to reschedule lost bilateral and domestic cricket. Moving the Men’s Cricket World Cup to a later window is a critical element of this and gives us a better chance of maintaining the integrity of the qualification process. This additional time will be used to reschedule games that might be lost because of the pandemic ensuring qualification can be decided on the field of play.

“Throughout this process we have worked closely with our key stakeholders including governments, Members, broadcasters, partners and medical experts to enable us to reach a collective decision for the good of the game and our fans. I would like to thank everyone involved for their commitment to a safe return to cricket.”

United Nations, Jan 2: Nearly 400,000 babies were born around the world on New Year's Day with India recording the highest number of these births worldwide at 67,385, the UN children's agency said.

An estimated 392,078 babies were born around the world on New Year's Day, according to UNICEF. Of this, an estimated 67,385 babies were born in India, the most globally. China comes in second with 46,299 births.

The beginning of a new year and a new decade is an opportunity to reflect on our hopes and aspirations not only for our future, but the future of those who will come after us,” UNICEF Executive Director Henrietta Fore said.

As the calendar flips each January, we are reminded of all the possibility and potential of each child embarking on her or his life's journey—if they are just given that chance.”

Fiji in the Pacific most likely delivered 2020's first baby, while the US, the last of the New Year's Day. Globally, over half of these births were estimated to have taken place in eight countries - India (67,385), China (46,299), Nigeria (26,039), Pakistan (16,787), Indonesia (13,020), United States of America (10,452), Democratic Republic of Congo (10,247) and Ethiopia (8,493).

Each January, UNICEF celebrates babies born on New Year's Day, an auspicious day for child birth around the world, it said. However, for millions of newborns around the world, the day of their birth is far less auspicious.

In 2018, 2.5 million newborns died in just their first month of life; about a third of them on the first day of life. Among those children, most died from preventable causes such as premature birth, complications during delivery, and infections like sepsis. In addition, more than 2.5 million babies are born dead each year.

UNICEF said over the past three decades, the world has seen remarkable progress in child survival, cutting the number of children worldwide who die before their fifth birthday by more than half. But there has been slower progress for newborns. Babies dying in the first month accounted for 47 per cent of all deaths among children under five in 2018, up from 40 per cent in 1990.

UNICEF's Every Child Alive campaign calls for immediate investment in health workers with the right training, who are equipped with the right medicines to ensure every mother and newborn is cared for by a safe pair of hands to prevent and treat complications during pregnancy, delivery and birth.

Too many mothers and newborns are not being cared for by a trained and equipped midwife or nurse, and the results are devastating,” said Fore. “We can ensure that millions of babies survive their first day and live into this decade and beyond if every one of them is born into a safe pair of hands.”

India is projected to surpass China as the world's most populous country around 2027. According to UN estimates, India is expected to add nearly 273 million people between 2019 and 2050, while the population of Nigeria is projected to grow by 200 million. Together, these two countries could account for 23 per cent of the global population increase to 2050.

China, with 1.43 billion people in 2019, and India, with 1.37 billion, have long been the two most populous countries of the world, comprising 19 and 18 per cent, respectively, of the global total in 2019. Through the end of the century, India is estimated to remain the world's most populous country with nearly 1.5 billion inhabitants, followed by China with just under 1.1 billion, Nigeria with 733 million, the US with 434 million, and Pakistan with 403 million inhabitants.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.